-+ 0.00%
-+ 0.00%
-+ 0.00%

ST Renfu (600079.SH): HW221043 tablets obtained approval notice for drug clinical trials

Zhitongcaijing·01/05/2026 08:57:06
Listen to the news

Zhitong Finance App News, ST Renfu (600079.SH) issued an announcement. Hubei Biomedical Industry Technology Research Institute Co., Ltd. (“Research Institute Co., Ltd.”), a wholly-owned subsidiary of the company, recently received the HW221043 “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. HW221043 tablets are intended for the treatment of advanced solid tumors. They are new molecular solid compounds independently developed by the company. Currently, no similar drugs have been approved for marketing at home or abroad. Up to now, the total R&D investment for HW221043 films is approximately RMB 24 million.